Jardiance® improves blood sugar control in type 2 diabetes
A Phase III trial showed Jardiance® is the first SGLT2 inhibitor to significantly reduce average blood sugar in type 2 diabetics aged 10-17 compared to placebo.
List view / Grid view
A Phase III trial showed Jardiance® is the first SGLT2 inhibitor to significantly reduce average blood sugar in type 2 diabetics aged 10-17 compared to placebo.
A major trial evaluating Boehringer Ingelheim’s Jardiance®, showed it reduced the risk of cardiovascular death and chronic kidney disease progression by 28 percent.
Outsourcing the production of oral solids is estimated to be the primary influencer for the contract manufacturing market in the next decade, using lessons learnt from the COVID-19 pandemic.
The pharmaceutical industry is bolstering aid for student research training in the UK, according to a survey produced by The Association of the British Pharmaceutical Industry (ABPI).
Aurobac Therapeutics SAS - a €40m joint venture between Boehringer Ingelheim, Evotec and bioMérieux - has been launched to create the next generation of antimicrobials and diagnostics to fight antimicrobial resistance (AMR).
Driven by oncology drug demand, the highly potent active pharmaceutical ingredients (HPAPIs) market is anticipated to grow by $7bn in three years.
The data from the 12 week trial showed phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 showed a reduction in the rate of lung function decline in patients with idiopathic pulmonary fibrosis (IPF).
Four Big Pharma companies have shared previously unpublished hazard data for drug substances to enhance database-dependent computational tools and help reduce animal testing.
An early halt has been called to a major kidney drug trial following positive results for patients with chronic kidney disease (CKD).
Phase III trial shows that adults hospitalised for acute heart failure were 36 percent more likely to experience a clinical benefit if initiated on empagliflozin.
Based on human resources and employee-centric practices, Takeda and Boehringer Ingelheim are among the top 11 employers worldwide.
Jardiance displayed a 21 percent risk reduction in adults with heart failure with preserved ejection fraction in Phase III study.
Market research suggests the Asia Pacific region could soon overtake Europe and North America in the active pharmaceutical ingredient (API) contract development and manufacturing organisation (CDMO) market.
Phase III trial data shows more than half of patients with moderate to severe Crohn's disease treated with risankizumab (Skyrizi®) 360mg achieved clinical remission in a year.
Research suggests the increasing R&D investment in and adoption of biologics will drive growth in the global biologics contract development and manufacturing organisation (CDMO) market.